Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Its lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. Ocaliva is approved in the US and the EU for use in primary biliary cholangitis.


Employee Rating

3.1More
TypePublic
HQNew York, US
Founded2002
Size (employees)507 (est)
Websiteinterceptpharma.com
Intercept Pharmaceuticals was founded in 2002 and is headquartered in New York, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Intercept Pharmaceuticals

Mark Pruzanski

Mark Pruzanski

Chief Executive Officer & President
Luciano Adorini

Luciano Adorini

Chief Scientific Officer
Show more

Intercept Pharmaceuticals Office Locations

Intercept Pharmaceuticals has offices in New York, Madrid, Lisboa, Milano and in 8 other locations
New York, US (HQ)
10 Hudson Yards
Wien, AT
1 Fleischmarkt
Mississauga, CA
90 Burnhamthorpe Rd W
Kongens Lyngby, DK
10C Lyngby Hovedgade
Paris, FR
21 Boulevard Haussmann
München, DE
52 Rosenheimer Str.
Show all (12)
Report incorrect company information

Intercept Pharmaceuticals Financials and Metrics

Intercept Pharmaceuticals Revenue

Intercept Pharmaceuticals's revenue was reported to be $130.96 m in FY, 2017
USD

Revenue (Q3, 2018)

47.0m

Gross profit (Q3, 2018)

46.5m

Gross profit margin (Q3, 2018), %

98.9%

Net income (Q3, 2018)

(64.5m)

EBIT (Q3, 2018)

(58.3m)

Market capitalization (22-Jan-2019)

3.3b

Closing stock price (22-Jan-2019)

110.9

Cash (30-Sep-2018)

59.4m

EV

3.6b
Intercept Pharmaceuticals's current market capitalization is $3.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.6m2.8m25.0m131.0m

Cost of goods sold

1.4m

Gross profit

129.6m

Gross profit Margin, %

99%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

405.4k405.4k445.4k445.4k445.0k445.0k5.5m5.2m21.0m30.9m41.3m36.0m43.6m47.0m

Cost of goods sold

97.0k279.0k172.0k280.0k713.0k519.0k

Gross profit

21.0m30.6m41.2m35.7m42.9m46.5m

Gross profit Margin, %

100%99%100%99%98%99%
Annual
usdY, 2009Y, 2010Y, 2011Y, 2012Y, 2013FY, 2013Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017

Cash

4.4m15.4m17.7m45.5m13.4m13.4m20.0m32.7m32.7m43.7m70.0m

Accounts Receivable

9.1m16.5m

Inventories

2.7m6.1m13.6m2.3m3.5m

Current Assets

147.6m147.6m245.8m641.7m641.7m707.9m448.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

33.5m11.2m45.0m18.1m104.4m88.3m72.4m49.2m51.7m105.2m67.0m62.0m120.2m48.9m77.7m59.4m

Accounts Receivable

10.6m13.2m14.5m16.9m19.5m22.1m

Inventories

2.1m2.7m3.9m7.9m5.8m7.5m

Current Assets

158.4m138.9m306.6m279.1m410.4m741.0m702.5m574.9m505.3m794.6m635.0m578.6m521.5m363.8m577.7m528.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(67.8m)(283.2m)(226.4m)(412.8m)(360.4m)

Depreciation and Amortization

105.7k442.8k1.7m3.8m4.6m

Inventories

(1.7m)(2.3m)(1.2m)

Accounts Payable

7.3m208.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(55.4m)(257.7m)(212.6m)(248.4m)(39.4m)(47.9m)(138.2m)(126.7m)(204.0m)(292.8m)(89.9m)(176.5m)(249.1m)(81.6m)(156.8m)(221.2m)

Depreciation and Amortization

61.7k130.4k210.2k1.1m684.0k1.5m2.2m802.0k1.9m3.3m1.3m2.4m3.6m

Inventories

163.0k(403.0k)(1.6m)(4.5m)(2.3m)(4.0m)

Accounts Payable

3.7m(3.5m)208.0k(3.5m)(3.7m)(3.7m)
USDY, 2018

EV/EBIT

-61.7 x

EV/CFO

-19.1 x

Debt/Equity

3.8 x

Debt/Assets

0.7 x

Financial Leverage

5.8 x
Show all financial metrics
Report incorrect company information

Intercept Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Intercept Pharmaceuticals News and Updates

Asia-Pacific Nonalcoholic Steatohepatitis Therapeutics Markets Report 2018-2024 Featuring Key Players - Allergan, Galmed, Genfit, Gilead, Intercept Pharmaceuticals & Zydus

DUBLIN, Jan. 16, 2019 /PRNewswire/ -- The "Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's offering. The NASH Asia-Pacific...

Intercept Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

Conference call scheduled for 8:30 a.m. ET today
Report incorrect company information

Intercept Pharmaceuticals Company Life and Culture

Report incorrect company information

Intercept Pharmaceuticals Frequently Asked Questions

  • When was Intercept Pharmaceuticals founded?

    Intercept Pharmaceuticals was founded in 2002.

  • Who are Intercept Pharmaceuticals key executives?

    Intercept Pharmaceuticals's key executives are Mark Pruzanski and Luciano Adorini.

  • How many employees does Intercept Pharmaceuticals have?

    Intercept Pharmaceuticals has 507 employees.

  • What is Intercept Pharmaceuticals revenue?

    Latest Intercept Pharmaceuticals annual revenue is $131 m.

  • What is Intercept Pharmaceuticals revenue per employee?

    Latest Intercept Pharmaceuticals revenue per employee is $258.3 k.

  • Who are Intercept Pharmaceuticals competitors?

    Competitors of Intercept Pharmaceuticals include MyoKardia, Athersys and Reata Pharmaceuticals.

  • Where is Intercept Pharmaceuticals headquarters?

    Intercept Pharmaceuticals headquarters is located at 10 Hudson Yards, New York.

  • Where are Intercept Pharmaceuticals offices?

    Intercept Pharmaceuticals has offices in New York, Madrid, Lisboa, Milano and in 8 other locations.

  • How many offices does Intercept Pharmaceuticals have?

    Intercept Pharmaceuticals has 12 offices.